Nicola Tinari - Concepedia

Author

Nicola Tinari

Also Known As

Caterina Fanizza, N TINARI, N Tinari, N. TINARI, N. Tinari, NICOLA TINARI, Nicola Tinari, Nicola Tinari (350375), T. Nicola, Tinari, N

226

Publications

7.7K

Citations

H-Index

129

Concepts

All Affiliations

University of Chieti-Pescara Ospedale SS. Annunziata University of L'Aquila Istituti di Ricovero e Cura a Carattere Scientifico Sapienza University of Rome

About

Nicola Tinari is an author at University of Chieti-Pescara specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	38	2.6K
2	Health Sciences	4	4	287
3	Natural Sciences	4	4	196
4	Engineering	2	2	91
5	Public Health	1	1	33

Nicola Tinari

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds Albana Cumashi, Natalia A. Ushakova, M. E. Preobrazhenskaya, Glycobiology	2007	1K
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, Journal for ImmunoTherapy of Cancer	2019	400
Concentrations of galectin-3 in the sera of normal controls and cancer patients. Ida Iurisci, Nicola Tinari, Clara Natoli, PubMed Galectin-3 Serum LevelsTumor InvasionLymphoid NeoplasiaNormal ControlsCancer Immunosurveillance	2000	290
Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties Paola Matarrese, O. Fusco, Nicola Tinari, International Journal of Cancer Cell SpreadingCell AdhesionApoptosisImmunologyCell Death	2000	235
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study Alessio Cortellini, Sebastiano Buti, Daniele Santini, The Oncologist ImmunologyImmunoeditingPathologyAnti-programmed Death-1 ImmunotherapyImmunotherapy	2019	214
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients Alessio Cortellini, Rita Chiari, Biagio Ricciuti, Clinical Lung Cancer Cancer ImmunosurveillanceAnti-pd1 ImmunotherapyImmunodeficienciesImmunologyClinical Trials	2019	174
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients Vincenzo Graziano, Antonino Grassadonia, Laura Iezzi, The Breast	2019	170
Galectin‐3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis Paola Matarrese, Nicola Tinari, Maria Letizia Semeraro, FEBS Letters MitophagyImmunologyCell DeathCytoskeletonMitochondrial Biology	2000	159
Fucans, but Not Fucomannoglucuronans, Determine the Biological Activities of Sulfated Polysaccharides from Laminaria saccharina Brown Seaweed Diego O. Croci, Albana Cumashi, Natalia A. Ushakova, PLoS ONE InflammationPolysaccharide FractionsAnti-inflammatoryBiochemistryMedicine	2011	149
Prognostic value of a novel circulating serum 90K antigen in breast cancer Stefano Iacobelli, P Sismondi, M Giai, British Journal of Cancer Prognostic BiomarkersBreast OncologyOncologyMedicinePrognostic Value	1994	121

Page 1